Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Dow
Moodys
Johnson and Johnson
Harvard Business School

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Litigation Details for ORTHO-MCNEIL PHARMACEUTICAL, INC. v. LUPIN PHARMACEUTICALS, INC. (D.N.J. 2006)

See Plans and Pricing

« Back to Dashboard

ORTHO-MCNEIL PHARMACEUTICAL, INC. v. LUPIN PHARMACEUTICALS, INC. (D.N.J. 2006)

Docket   Start Trial Date Filed 2006-10-17
Court District Court, D. New Jersey Date Terminated 2009-05-01
Cause 35:145 Patent Infringement Assigned To Garrett E. Brown Jr.
Jury Demand None Referred To Magistrate Judge Tonianne J. B
Parties DAIICHI PHARMACEUTICAL CO., LTD.; DAIICHI SANKYO COMPANY, LIMITED; LUPIN LTD.; LUPIN PHARMACEUTICALS, INC.; ORTHO-MCNEIL PHARMACEUTICAL, INC.; ORTHO-MCNEIL, INC.
Patents 4,382,892; 5,053,407
Attorneys CHARLES MICHAEL LIZZA; DAVID C. KISTLER; JONATHAN M.H. SHORT; KAREN A. CONFOY; MARK H. ANANIA; MICHAEL A. LAMPERT; THOMAS EVAN HASTINGS; WILLIAM C. BATON; WILLIAM J. HELLER
Firms Bgc Partners; Blank Rome LLP; McCarter & English, LLP; Smith, Stratton, Wise, Heher & Brennan, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in ORTHO-MCNEIL PHARMACEUTICAL, INC. v. LUPIN PHARMACEUTICALS, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for ORTHO-MCNEIL PHARMACEUTICAL, INC. v. LUPIN PHARMACEUTICALS, INC. (D.N.J. 2006)

Date Filed Document No. Description Snippet Link To Document
2007-02-15 14 Code for infringement of ‘U.S. Patent No. 5,053,407 (“the ‘407 patent”) and that this Court has subject…the United States Patent and Trademark Office on March 10, 2000 for the ‘407 patent, allegedly under the…the United States Patent and Trademark Office on March 10, 2000 for the ‘407 patent, allegedly under the… invalid extension of patent term and non- infringement arising under the patent laws of the United States…infringement of United States Patent No. 5,053,40'7 (“the ‘40'7 patent”) . 10. There is an actual External link to document
2008-08-29 55 valid claim of Plaintiffs’ U.S. Patent No. 5,053,407 (the ’407 patent”). (Id. at Ex. B; Plaint. Br. at… ‘407 patent. (Id.) Defendants did not argue in their notice letter that the ‘407 patent was invalid…the ‘407 patent was not eligible for the extension it was granted by the FDA and the Patent and Trademark…Plaint Br. at 4.) According to Defendants, the ‘407 patent was not eligible for extension because Plaintiffs…active ingredient in Levaquin (covered by the ‘407 patent) is (+) ofloxacin, which is an active ingredient External link to document
2009-05-01 73 United States Patent and Trademark Office (“PTO”) issued U.S. Patent 4,382,892 (the “‘892 Patent”) to Plaintiff…the Board of Patent Appeals and Interferences granted judgment to Daiichi, and U.S. Patent 5,053,407 (…tablet formulations of Levofloxacin as patented in the ‘407 Patent. (Defs.’ R. 56.1 ¶ 16. [#59]; Pl.’s R… Resp. ¶ 16. [#61]) The Levofloxacin patented in the ‘407 Patent has been subsequently marketed under…pharmaceutical formulations of Levofloxacin as patented in the ‘407 Patent. (Defs.’ R. 56.1 ¶ 24. [#59]; Pl.’s External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Merck
Mallinckrodt
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.